Indonesia is rapidly embracing biotech investment to lower healthcare costs and reinforce its national health insurance scheme, JKN. Valued at over USD 2 billion and growing, the sector faces challenges in R&D and skilled workforce development but promises transformative, cost-effective treatments and reduced reliance on pharmaceutical imports.
As the first Southeast Asian nation to deploy mRNA vaccine technology, Indonesia is advancing initiatives such as the Biomedical & Genome Science Initiative to drive precision medicine. Key investment opportunities span biopharmaceuticals and vaccine production, R&D support and testing services, supply chain solutions and certification, raw materials and advanced biotech products.
With major players like Daewoong, Pfizer and Kalbe Farma expanding operations—primarily in Java—Indonesia’s growing biotech ecosystem offers significant potential for early foreign investors amid rising healthcare demands. Explore how Indonesia is shaping the future of healthcare through biotechnology and what this means for global investment.
Subscribe to Asian Insiders for expert insights on Asia’s biggest opportunities!
